
IASLC/LinkedIn
Jun 26, 2025, 06:06
Listen to the New Episode of Lung Cancer Considered on the FDA Approval of Taletrectinib for ROS1-Positive NSCLC – IASLC
International Association for the Study of Lung Cancer shared a post on LinkedIn:
“The FDA has approved taletrectinib, a next-generation ROS1 inhibitor for NSCLC. But how does this new therapy compare with existing options—and where does it fit in the treatment landscape?
In this Lung Cancer Considered episode, Dr. Stephen Liu speaks with Dr. Enriqueta Felip and Dr. Jorge Nieva to break down the data behind the approval and discuss how clinicians can thoughtfully integrate taletrectinib into practice.
More posts featuring IASLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 05:56
Jun 26, 2025, 05:51
Jun 26, 2025, 05:45
Jun 26, 2025, 03:19